Arvinas Operations patents new Raf kinase B mutant degradation inducers
April 5, 2024
Arvinas Operations Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds consisting of a cereblon E3 ubiquitin ligase binding moiety coupled to a Raf kinase B G466V and/or V600E mutant targeting agent through a linker.